謝 茂志

Medicine & Life Sciences

1. Stomach Neoplasms 100%
2. Gastrectomy 44%
3. Stomach 41%
4. Adenocarcinoma 41%
5. Survival 40%
6. Neoplasm Metastasis 37%
7. Induced Hyperthermia 32%
8. Neoplasms 31%
9. Carcinoma 30%
10. Cytoreduction Surgical Procedures 27%
11. Lymph Nodes 26%
12. Peritoneal Neoplasms 22%
13. Taiwan 19%
14. Recurrence 18%
15. Survival Rate 15%
16. Gastric Stump 10%
17. Morbidity 10%
18. Pseudomyxoma Peritonei 10%
19. Drug Therapy 10%
20. Lymph Node Excision 9%
21. Signet Ring Cell Carcinoma 9%
22. Adjuvant Chemotherapy 8%
23. Anastomotic Leak 8%
24. Mortality 7%
25. Goblet Cells 7%
26. Liver 7%
27. Chemoradiotherapy 7%
28. Risk Management 7%
29. Registries 6%
30. Randomized Controlled Trials 6%
31. Multivariate Analysis 6%
32. Breast Neoplasms 6%
33. Dissection 6%
34. Therapeutics 6%
35. Splenectomy 6%
36. Veterans Hospitals 6%
37. Bazex-Dupre-Christol syndrome 5%
38. Confidence Intervals 5%
39. Breast 5%
40. Abdominal Abscess 5%
41. Adjuvant Chemoradiotherapy 5%
42. Serous Membrane 5%
43. Adjuvant Radiotherapy 5%
44. Disease-Free Survival 5%
45. Tissue Polypeptide Antigen 5%
46. Hepatocellular Carcinoma 5%
47. Colorectal Neoplasms 5%
48. Urachus 5%